| 0.7136 0.006 (0.9%) | 04-22 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.01 | 1-year : | 2.76 |
| Resists | First : | 1.72 | Second : | 2.36 |
| Pivot price | 0.83  |
|||
| Supports | First : | 0.68 | Second : | 0.57 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.94 |
| MA(100) : | 1.16 |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 5.7 |
D(3) : | 3.9 |
| RSI | RSI(14): 29.9 |
|||
| 52-week | High : | 6.16 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DRMA ] has closed above bottom band by 23.8%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.73 - 0.73 | 0.73 - 0.73 |
| Low: | 0.68 - 0.68 | 0.68 - 0.69 |
| Close: | 0.7 - 0.71 | 0.71 - 0.71 |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Tue, 15 Apr 2025
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Tue, 15 Apr 2025
Dermata Therapeutics Inc - Announces Topline Results From Phase 3 Trial Of Xyngari - SEC Filing - marketscreener.com
Wed, 09 Apr 2025
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Fri, 28 Mar 2025
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
Thu, 27 Mar 2025
First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan
Thu, 27 Mar 2025
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 23.2 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 189 (K) |
| Shares Short P.Month | 278 (K) |
| EPS | -8.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -135.9 % |
| Return on Equity (ttm) | -310.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|